EP Patent

EP3939574A1 — Delayed release cysteamine bead formulation

Assigned to Horizon Therapeutics US Holding LLC · Expires 2022-01-19 · 4y expired

What this patent protects

An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.

USPTO Abstract

An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.

Drugs covered by this patent

cysteamine-bitartrate (CYSTEAMINE BITARTRATE)

Patent Metadata

Patent number: EP3939574A1
Jurisdiction: EP
Classification: —
Expires: 2022-01-19
Drug substance claim: No
Drug product claim: No
Assignee: Horizon Therapeutics US Holding LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.